Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Yes, breakthrough measles can happen after vaccination, though it is uncommon, since two MMR doses are about 97% effective and one dose is roughly 93% effective. When vaccinated people are infected, the illness is usually milder and shorter, often with lower fever, a fainter or more limited rash, fewer complications, and reduced likelihood of spreading the virus to others. Several factors still shape your personal risk and symptom severity, including how many doses you received, time since vaccination, immune system health, and how intense the exposure was, so see below for the details that matter most.
Because early measles can look like many ordinary viral illnesses, a free, instant, online symptom check can help you clarify what is likely causing your fever, rash, or cough and what step to take next. It takes only a few minutes, works anytime from your phone, and can guide you toward the right level of care before symptoms progress or you unknowingly expose someone vulnerable.
Last reviewed for medical accuracy: 10/01/2026
Measles is one of the most contagious viral diseases known. Thanks to the measles–mumps–rubella (MMR) vaccine, cases have plummeted worldwide. But even with vaccination, a small number of people can still catch measles. Here’s what you need to know in clear, straightforward terms—no fluff, no undue alarm.
High levels of protection mean that most vaccinated people never see measles. But because no vaccine is 100% foolproof, about 3 in every 100 fully vaccinated individuals remain susceptible.
Breakthrough measles refers to infection in someone who has been vaccinated. Two main reasons explain why it can occur:
Primary vaccine failure
Secondary vaccine failure (waning immunity)
Other factors that raise risk:
When vaccinated people do get measles, their symptoms are almost always less severe than those in unvaccinated individuals. Here’s how breakthrough cases tend to differ:
Shorter duration.
Fever and rash often last fewer days.
Lower peak fever.
High fevers over 104 °F (40 °C) are uncommon in vaccinated people.
Milder rash.
Fewer spots that may be lighter in color or cover less of the body.
Fewer complications.
Ear infections, pneumonia, encephalitis, and other serious complications occur much less often.
| Symptom | Unvaccinated Person | Vaccinated Person (Breakthrough) |
|---|---|---|
| Fever | Often > 104 °F (40 °C) | Usually < 104 °F |
| Rash duration | 5–6 days | 2–4 days |
| Rash appearance | Dense, widespread | Sparse or lighter |
| Cough / runny nose / red eyes | Prominent (“3 C’s”) | Milder, shorter-lived |
| Hospitalization risk | ~ 1–2 per 1,000 cases | Significantly lower |
| Serious complications | 1 in 10 (otitis media, pneumonia) | Rare |
If you fall into one of these groups, you may wish to talk to your doctor about getting (or re-getting) vaccinated, or about post-exposure measures if you think you’ve been exposed.
Measles typically begins with:
If you or your child have these symptoms—especially after known exposure—you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get tailored guidance.
Most breakthrough cases resolve on their own with rest, fluids, and over-the-counter fever reducers. However, you should contact a healthcare professional if you notice:
Even if you’ve had measles in the past, vaccination is still recommended, since natural infection doesn’t always guarantee lifelong protection.
Can you still get measles after vaccination? Yes—but it’s rare, and the illness is almost always much milder than in unvaccinated people. The MMR vaccine remains our best defense, cutting risk by over 90% with one dose and more than 97% with two.
If you suspect measles or any serious illness, don’t hesitate. Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker, and speak to a doctor about any signs that could be life threatening or serious. Your health—and that of your loved ones—depends on prompt evaluation.
(References)
* Aaby P, Jensen TG, Hansen HL, Kristiansen H, Thårup J, Poulsen A, Sodemann M, Jakobsen M, Knudsen K, Clotilde da Silva M. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet. 1988 Oct 8;2(8615):809-11. doi: 10.1016/s0140-6736(88)92780-8. PMID: 2902263.
* Wang W, O'Driscoll M, Wang Q, Zhao S, Salje H, Yu H. Dynamics of measles immunity from birth and following vaccination. Nat Microbiol. 2024 Jul;9(7):1676-1685. doi: 10.1038/s41564-024-01694-x. Epub 2024 May 13. PMID: 38740931.
* BUDAI J, FARKAS E, NYERGES G, CSAPO J. [ACTIVE IMMUNIZATION AGAINST MEASLES]. Orv Hetil. 1965 Jan 3;106:7-11. PMID: 14248048.
* KRUGMAN S. MEASLES IMMUNIZATION: COMBINED VACCINATIONS. Arch Gesamte Virusforsch. 1965;16:339-42. doi: 10.1007/BF01253834. PMID: 14322890.
* Hijano DR, Orenstein WA, Oliveira CR. Measles Resurgence and the Fragility of Herd Immunity: Implications for Pediatric Infectious Disease Practice. J Pediatric Infect Dis Soc. 2025 Nov 1;14(11). doi: 10.1093/jpids/piaf094. PMID: 41105102; PMCID: PMC12581858.
* GARD S, CARLSTROEM G, LAGERCRANTZ R, NORRBY E. IMMUNIZATION WITH INACTIVATED MEASLES VIRUS VACCINE. Arch Gesamte Virusforsch. 1965;16:315-23. doi: 10.1007/BF01253829. PMID: 14322885.
* KATZ SL. IMMUNIZATION WITH LIVE ATTENUATED MEASLES VIRUS VACCINES: FIVE YEARS' EXPERIENCE. Arch Gesamte Virusforsch. 1965;16:222-30. doi: 10.1007/BF01253813. PMID: 14322868.
* SPENCER IW, COSTER MB, RICHTER M, MAHER M. A FIELD EXPERIENCE OF COMBINED MEASLES, DIPHTHERIA, WHOOPING COUGH AND TETANUS IMMUNIZATION. S Afr Med J. 1964 Feb 8;38:103-8. PMID: 14128151.
* MARTIN CM, MANFREDONIA SJ, WEBB NC Jr, MARKHAM FS, RUEGSEGGER JM. CONTROLLED TRIAL OF LIVE MEASLES VACCINE. EFFECTS OF AGE, HISTORY OF MEASLES IN SIBLINGS, PREVACCINE ANTIBODY, AND HUMAN GAMMA-GLOBULIN ON SYMPTOMATIC AND IMMUNE RESPONSES. Am J Dis Child. 1963 Sep;106:267-79. PMID: 14057606.
* Clifford HD, Hayden CM, Khoo SK, Naniche D, Mandomando IM, Zhang G, Richmond P, Le Souëf PN. Impact of CD14 promoter variants on measles vaccine responses and vaccine failure in children from Australia and Mozambique. Tissue Antigens. 2013 Dec;82(6):420-2. doi: 10.1111/tan.12226. Epub 2013 Oct 21. PMID: 24147858.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.